Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions

Still dying in plain sight: missed and misclassified deaths due to tuberculosis in hospitals

Byron William Patrick Reeve, Rosella Centis, Grant Theron
European Respiratory Journal 2019 54: 1901578; DOI: 10.1183/13993003.01578-2019
Byron William Patrick Reeve
1NRF/DST Centre of Excellence for Biomedical Tuberculosis Research; South African Medical Research Council Centre for Tuberculosis Research; Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rosella Centis
2Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri IRCCS, Tradate, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rosella Centis
Grant Theron
1NRF/DST Centre of Excellence for Biomedical Tuberculosis Research; South African Medical Research Council Centre for Tuberculosis Research; Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Grant Theron
  • For correspondence: gtheron@sun.ac.za
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

The study reported by Garcia-Basterio and co-workers has used Xpert MTB/RIF Ultra in cadavers for the first time, to improve detection of TB cases that would have ordinarily been missed by histology or clinical examination. http://bit.ly/2P9Zpyz

Diagnostic tests for tuberculosis (TB) have undergone an era of unprecedented innovation [1]. Over the past century, the bacteriological diagnosis of TB was primarily based on sputum smear microscopy and culture (solid and subsequently liquid culture). Rapid new molecular tests have been introduced, including the automated nucleic acid amplification test Xpert MTB/RIF (Xpert) and its recent successor Xpert MTB/RIF Ultra (Ultra) [2–4]. Diagnostic algorithms have been developed that combine these new tests with established tools [5–7]; however, such algorithms are often country- or setting-specific, depending on test availability, differ in quality of implementation [2–4, 8], and are infrequently deployed in decedents.

The study by Garcia-Basterio et al. [9] shows that the benefits offered by new tests are yet to fully filter down to the patients who likely stand to benefit the most (i.e. the sickest patients, who are often inpatients at centralised hospitals). For example, Xpert has proven utility in such patients, including when done on non-sputum specimens [10–12], as does the bedside urine-based Alere lateral flow LAM assay [13], which is the only TB test with randomised clinical trial evidence of a mortality benefit [14], and the promising new urine-based FujiFilm SILVAMP assay [15]. Ultra itself has improved sensitivity for pulmonary TB compared to Xpert [16] but Ultra's utility in establishing TB as a cause of death in hospitalised decedents is hitherto undescribed.

Sensitive tests are critical for identifying missed cases and, when combined with autopsies, guiding TB mortality estimates [17, 18]. Such estimates can inform the effectiveness of TB control measures and, as exemplified by the current study, establish when pre-mortem diagnoses are incorrect. The latter can be due to non-specific symptoms and the limited availability and sensitivity of TB tests (sensitivity is worse in HIV-positive patients due to paucibacillary disease) [19–21]. Furthermore, incorrect or incomplete pre-mortem diagnoses can preclude further investigation. In other words, once an initial diagnosis is established, potential comorbid TB may not be investigated. Finding these missing cases is the major thrust of the World Health Organization (WHO) End TB initiative [22–26].

An early systematic review and meta-analysis of 3237 autopsies in HIV-positive people found TB to be the cause of death in 39% of adult decedents [17]. In those who died of TB, 46% were undiagnosed at the time of death. Subsequent autopsy studies (table 1) continue to highlight that the status quo has essentially remained unchanged. There thus continues to be high transmission risk to health workers and other patients from undiagnosed TB cases in hospitals. As discussed in a WHO document [27], one solution to limit nosocomial TB transmission is the FAST framework (Find cases Actively, Separate safely, and Treat effectively) which could, for example, be deployed in facilities where autopsies indicate a large burden of undiagnosed TB [28].

View this table:
  • View inline
  • View popup
TABLE 1

Selection of recent mortality studies amongst hospitalised decedents

Importantly, the aforementioned meta-analysis [17] pre-dated studies that used Xpert. TB detection was thus primarily based on clinical signs and symptoms in combination with smear microscopy and the histological staining of tissue lesions [17, 29]. These tests have suboptimal sensitivity for TB and are typically not done systematically in patients or decedents unless TB was suspected. However, hospitals in high burden settings do not have the capacity and infrastructure to adequately screen and test all inpatients. This is despite a large body of evidence that has consistently proven high burdens of undiagnosed TB in hospitals in endemic countries [14, 30], and the obvious but important fact that these patients represent an easily accessible and semi-captive population. Hence, without the systematic use of new molecular tools, irrespective of the suspected reason for admission, it is likely that diagnoses will continue to be missed in hospitals in high burden countries. Furthermore, without the use of these tools as part of autopsies (irrespective of the suspected reason for death), it is likely that the frequency of TB in decedents will continue to be poorly characterised and we will miss critical data on the performance of TB control interventions. There are also limited data on the frequency and type of comorbidities in which TB occurs amongst decedents. This might prove useful to guide further investigations once a primary diagnosis with a known high rate of comorbid TB is established.

Garcia-Basterio et al. [9] report the first use of Ultra for TB detection in cadavers [9]. Using DNA-based tests, including Ultra and an in-house PCR, the authors found 14% of deaths in children and adults (excluding trauma) were caused by TB. Alarmingly, when compared to their complete diagnostic autopsy reference standard, 80% of these TB diagnoses were missed pre-mortem before routine PCR testing was implemented at the facility. Critically, many TB decedents did not report cough or fever at admission. This is indicative of the poor utility (and likely quality) of symptom screening and highlights the importance of having a screening threshold for TB as low as feasibly possible (all HIV-positive patients should be tested).

Importantly, many patients in the study were Ultra-positive for TB, but histology-negative, making use of the latter technique increasingly hard to justify in the molecular era, especially where this is a risk of drug resistance. However, in the case of previous TB that, as a result of remnant mycobacterial DNA, can cause false-positive PCR results [31, 32], histology and other diagnostic modalities may have utility when the clinical picture is not compatible with TB.

Lastly, the study suggests hospitals in high burden settings should routinely do autopsies combined with thorough investigations for TB, especially in a subset of decedents with high risk. This would, for example, serve as a useful tool to monitor if case detection at admission was sufficiently effective and a proxy of the quality of the diagnostic and treatment programme (including for latent TB infection) in the absence of or complementary to a prevalence survey [22–26]. Such a readout must be linked with interventions that strengthen health worker education and training so that lapses in TB diagnosis or nosocomial infection control can be readily addressed.

Strengths of the study include it being the first evaluation of Ultra in decedents, use of a rigorous diagnostic autopsy reference standard in a large cohort, and an underrepresented setting (Mozambique) where only one previous TB autopsy study has been done [33]. Limitations include a lack of culture, which may help clarify the nature of Ultra-positive results (especially trace results) especially in the absence of other positive results, and the use of Ultra only in a subset of decedents (Ultra's yield, and consequently the rates of TB in decedents, is hence likely underestimated).

So, what are the next steps? We know that TB diagnosed in hospitals in Africa is the tip of the iceberg, that health workers and facilities are unable to routinely identify all patients who need TB testing (such patients often do not have symptoms), there is evidence that new tools (including non-sputum tools) have utility and save lives [13–15, 34] and, perhaps most importantly, that the patients are already right under our noses in hospitals. Clearly, all patients entering hospitals in high burden, HIV endemic settings should be universally tested for TB, irrespective of symptoms. Furthermore, all decedents receiving an autopsy should undergo molecular testing for TB. The status quo in high burden settings is otherwise indefensible. Urgent implementation action from political, national programme, and activist communities is required.

Shareable PDF

Supplementary Material

This one-page PDF can be shared freely online.

Shareable PDF ERJ-01578-2019.Shareable

Footnotes

  • Conflict of interest: B.W.P. Reeve reports in-kind donations of Xpert Ultra cartridges for an unrelated study and travel support to attend a conference from Cepheid, in-kind donations of MTBDRplus test strips for an unrelated study from Hain Lifesciences, outside the submitted work.

  • Conflict of interest: R. Centis has nothing to disclose.

  • Conflict of interest: G. Theron reports in-kind donations of Xpert Ultra cartridges for an unrelated study from Cepheid, and in-kind donations and financial support from Hain Lifesciences for an unrelated study.

  • Received August 7, 2019.
  • Accepted August 10, 2019.
  • Copyright ©ERS 2019
https://www.ersjournals.com/user-licence

References

  1. ↵
    1. García-Basteiro AL,
    2. DiNardo A,
    3. Saavedra B, et al.
    Point of care diagnostics for tuberculosis. Pulmonology 2018; 1: 73–85.
    OpenUrl
  2. ↵
    1. Tagliani E,
    2. Nikolayevskyy V,
    3. Tortoli E
    . Laboratory diagnosis. In: Migliori GB, Bothamley G, Duarte R, et al., eds. Tuberculosis (ERS Monograph). Sheffield, European Respiratory Society, 2018; pp. 99–115.
    1. Sulis G,
    2. Agliati A,
    3. Pinsi G, et al.
    Xpert MTB/RIF as add-on test to microscopy in a low tuberculosis incidence setting. Eur Respir J 2018; 51: 1702345.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Albert H,
    2. Nathavitharana RR,
    3. Isaacs C, et al.
    Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better? Eur Respir J 2016; 48: 516–525.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Nahid P,
    2. Dorman SE,
    3. Alipanah N, et al.
    Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis 2016; 63: e147–e195.
    OpenUrlCrossRefPubMed
  5. World Health Organization. Guidelines for treatment of drug-susceptible tuberculosis and patient care, 2017 update. Geneva, World Health Organization, 2017. Document WHO/HTM/TB/2017.05.
  6. ↵
    World Health Organization. Consolidated guidelines on drug-resistant tuberculosis treatment. Geneva, World Health Organization, 2019. Document WHO/CDS/TB/2019.7.
  7. ↵
    1. Cazabon D,
    2. Suresh A,
    3. Oghor C, et al.
    Implementation of Xpert MTB/RIF in 22 high tuberculosis burden countries: are we making progress? Eur Respir J 2017; 50: 1700918.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Garcia-Basteiro AL,
    2. Hurtado JC,
    3. Castillo P, et al.
    Unmasking the hidden tuberculosis mortality burden in a large post mortem study in Maputo Central Hospital, Mozambique. Eur Respir J 2019; 54: 1900312.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Yoon C,
    2. Cattamanchi A,
    3. Davis JL, et al.
    Impact of Xpert MTB/RIF testing on tuberculosis management and outcomes in hospitalized patients in Uganda. PLoS One 2012; 7: e48599.
    OpenUrlCrossRefPubMed
    1. Calligaro GL,
    2. Theron G,
    3. Khalfey H, et al.
    Burden of tuberculosis in intensive care units in Cape Town, South Africa, and assessment of the accuracy and effect on patient outcomes of the Xpert MTB/RIF test on tracheal aspirate samples for diagnosis of pulmonary tuberculosis: a prospective burden of disease study with a nested randomised controlled trial. Lancet Respir Med 2015; 3: 621–630.
    OpenUrl
  10. ↵
    1. Peter JG,
    2. Theron G,
    3. Muchinga TE, et al.
    The diagnostic accuracy of urine-based Xpert MTB/RIF in HIV-infected hospitalized patients who are smear-negative or sputum scarce. PLoS One 2012; 7: e39966.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Peter JG,
    2. Zijenah LS,
    3. Chanda D, et al.
    Effect on mortality of point-of-care, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV-positive hospital inpatients: a pragmatic, parallel-group, multicountry, open-label, randomised controlled trial. Lancet 2016; 387: 1187–1197.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Gupta-Wright A,
    2. Corbett EL,
    3. van Oosterhout JJ, et al.
    Rapid urine-based screening for tuberculosis in HIV-positive patients admitted to hospital in Africa (STAMP): a pragmatic, multicentre, parallel-group, double-blind, randomised controlled trial. Lancet 2018; 392: 292–301.
    OpenUrl
  13. ↵
    1. Broger T,
    2. Sossen B,
    3. du Toit E, et al.
    Novel lipoarabinomannan point-of-care tuberculosis test for people with HIV: a diagnostic accuracy study. Lancet 2019; 19: 852–861.
    OpenUrl
  14. ↵
    1. Horne DJ,
    2. Kohli M,
    3. Zifodya JS, et al.
    Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev 2019; 6: CD009593.
    OpenUrl
  15. ↵
    1. Glaziou P,
    2. Dodd PJ,
    3. Zignol M, et al.
    Methods used by WHO to estimate the global burden of TB disease. Online Technical Appendix World Health Organization Global tuberculosis report 2018. www.who.int/tb/publications/global_report/gtbr2018_online_technical_appendix_global_disease_burden_estimation.pdf Date last accessed: 29 July, 2019.
  16. ↵
    1. Karat AS,
    2. Tlali M,
    3. Fielding KL, et al.
    Measuring mortality due to HIV-associated tuberculosis among adults in South Africa: Comparing verbal autopsy, minimally-invasive autopsy, and research data. PLoS One 2017; 12: e0174097.
    OpenUrl
  17. ↵
    1. Gupta RK,
    2. Lucas SB,
    3. Fielding KL, et al.
    Prevalence of tuberculosis in post-mortem studies of HIV-infected adults and children in resource-limited settings: a systematic review and meta-analysis. AIDS 2015; 29: 1987–2002.
    OpenUrlCrossRefPubMed
    1. Beadsworth M,
    2. Cohen D,
    3. Ratcliffe L, et al.
    Autopsies in HIV: still identifying missed diagnoses. Int J STD AIDS 2009; 20: 84–86.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Peter JG,
    2. Theron G,
    3. Singh N, et al.
    Sputum induction to aid the diagnosis of smear-negative or sputum-scarce TB in adults from a HIV-endemic setting. Eur Respir J 2014; 43: 185–194.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    World Health Organization. The End TB Strategy. Global strategy and targets for tuberculosis prevention, care and control after 2015. Geneva, World Health Organization, 2014. www.who.int/tb/strategy/en/ Date last accessed: 29 July, 2019.
    1. Raviglione MC
    . Evolution of the strategies for control and elimination. In: Migliori GB, Bothamley G, Duarte R, et al., eds. Tuberculosis (ERS Monograph). Sheffield, European Respiratory Society, 2018; pp. 36–61.
    1. Lönnroth K,
    2. Migliori GB,
    3. Abubakar I, et al.
    Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J 2015; 45: 928–952.
    OpenUrlAbstract/FREE Full Text
    1. D'Ambrosio L,
    2. Dara M,
    3. Tadolini M, et al.
    Tuberculosis elimination: theory and practice in Europe. Eur Respir J 2014; 43: 1410–1420.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Matteelli A,
    2. Rendon A,
    3. Tiberi S, et al.
    Tuberculosis elimination: where are we now? Eur Respir Rev 2018; 27: 180035.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Migliori GB,
    2. Nardell E,
    3. Yedilbayev A, et al.
    Reducing tuberculosis transmission: a consensus document from the World Health Organization Regional Office for Europe. Eur Respir J 2019; 53: 1900391.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Barrera E,
    2. Livchits V,
    3. Nardell E
    . FAST: a refocused, intensified, administrative tuberculosis transmission control strategy. Int J Tuberc Lung Dis 2015; 19: 381–384.
    OpenUrlCrossRefPubMed
  23. ↵
    1. Diedrich CR,
    2. O'Hern J,
    3. Wilkinson RJ
    . HIV-1 and the Mycobacterium tuberculosis granuloma: a systematic review and meta-analysis. Tuberculosis 2016; 98: 62–76.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Lawn SD,
    2. Kerkhoff AD,
    3. Burton R, et al.
    Rapid microbiological screening for tuberculosis in HIV-positive patients on the first day of acute hospital admission by systematic testing of urine samples using Xpert MTB/RIF: a prospective cohort in South Africa. BMC Med 2015; 13: 192.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Theron G,
    2. Venter R,
    3. Smith L, et al.
    False positive Xpert MTB/RIF results in re-tested patients with previous tuberculosis: frequency, profile, and prospective clinical outcomes. J Clin Microbiol 2018; 56: e01696–17.
    OpenUrl
  26. ↵
    1. Theron G,
    2. Venter R,
    3. Calligaro G, et al.
    Xpert MTB/RIF results in patients with previous tuberculosis: can we distinguish true from false positive results? Clin Infect Dis 2016; 62: 995–1001.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Carrilho C,
    2. Monteiro E,
    3. Ussene E, et al.
    causes of death in HIV/AIDS patients in Maputo Central Hospital-a retrospective study from 2010. Histopathology 2012; 61: Suppl. 1, 1–2.
    OpenUrlPubMed
  28. ↵
    1. Di Tanna GL,
    2. Khaki AR,
    3. Theron G, et al.
    Effect of Xpert MTB/RIF on clinical outcomes in routine care settings: individual patient data meta-analysis. Lancet Glob Health 2019; 7: e191–e199.
    OpenUrl
    1. Ford N,
    2. Matteelli A,
    3. Shubber Z, et al.
    TB as a cause of hospitalization and in-hospital mortality among people living with HIV worldwide: a systematic review and meta-analysis. J Int AIDS Soc 2016; 19: 20714.
    OpenUrl
    1. Bates M,
    2. Mudenda V,
    3. Shibemba A, et al.
    Burden of tuberculosis at post mortem in inpatients at a tertiary referral centre in sub-Saharan Africa: a prospective descriptive autopsy study. Lancet Infect Dis 2015; 15: 544–551.
    OpenUrlCrossRefPubMed
    1. Saavedra A,
    2. Campinha-Bacote N,
    3. Hajjar M, et al.
    Causes of death and factors associated with early mortality of HIV-infected adults admitted to Korle-Bu Teaching Hospital. Pan Afr Med J 2017; 18: 27–48.
    OpenUrl
PreviousNext
Back to top
View this article with LENS
Vol 54 Issue 3 Table of Contents
European Respiratory Journal: 54 (3)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Still dying in plain sight: missed and misclassified deaths due to tuberculosis in hospitals
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Still dying in plain sight: missed and misclassified deaths due to tuberculosis in hospitals
Byron William Patrick Reeve, Rosella Centis, Grant Theron
European Respiratory Journal Sep 2019, 54 (3) 1901578; DOI: 10.1183/13993003.01578-2019

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Still dying in plain sight: missed and misclassified deaths due to tuberculosis in hospitals
Byron William Patrick Reeve, Rosella Centis, Grant Theron
European Respiratory Journal Sep 2019, 54 (3) 1901578; DOI: 10.1183/13993003.01578-2019
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Shareable PDF
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Sotatercept, haemodynamics and the right ventricle
  • GOLD 2023 streamlines pharmacological treatment
  • The ERS PROFILE.net Clinical Research Collaboration
Show more Editorials

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society